Close Menu

gene signature

A team compared expression in duodenum samples from active celiac cases, cases in remission, and unaffected controls, identifying active disease-related expression shifts.

A study exploring adjuvant capecitabine in early-stage TNBC failed but researchers are performing genomic analysis on a subset of patients who benefited.

 

Researchers characterized genetic, transcriptomic, and clinical features in advanced prostate cancers that emerged from treatment.

Focusing on drugs that appeared to reverse cancer-related gene expression signatures, researchers identified candidate compounds that thwarted cancer cell lines.

The PAM50 breast cancer classifier successfully split prostate cancer samples into luminal and basal subtypes with ties to patient outcomes and treatment response.

A team led by University of Toronto researchers developed the signature as a clinical assay that could predict treatment response.

This Week in Science

In Science this week: gene mutation signatures linked to tobacco smoke, and more.

Researchers have developed a gene expression signature of healthy aging that can identify people at risk of Alzheimer's disease.

The study results also offer hints to new pathways that might be targeted to overcome resistance to currently used DNA methyltransferase inhibitors.

Led by former LabCorp executives, the firm is aiming to develop evidence around genetic signatures and license the tech to labs and Dx developers.

Pages

Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.

Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.

New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.

In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.